Your session is about to expire
← Back to Search
Cisgender Women and Trans Individuals (CWTI) for Pre-Exposure Prophylaxis (S2P:CWTI Trial)
S2P:CWTI Trial Summary
This trial will evaluate attitudes and preferences about HIV prevention options over time, among people who are taking medication to prevent HIV, and among people who are not taking medication but are at risk of HIV.
- HIV Prevention
- Pre-Exposure Prophylaxis
S2P:CWTI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.S2P:CWTI Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Women and transgender individuals who are eligible for PrEP have decided to either take it, not take it, or stop taking it.
- Group 1: Cisgender Women and Trans Individuals (CWTI)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any openings for enrollment in this research initiative?
"Affirmative, the clinicaltrials.gov website states that this research is presently enrolling participants. The trial was initially publicized on October 25th 2021 and its most recent update occurred on December 8th 2021. There are 175 open spots at a single site for interested individuals to join the study."
What is the maximum number of individuals permissible to partake in this research?
"Affirmative. The details on clinicaltrials.gov demonstrate that the study, which initially went live on October 25th 2021, is presently recruiting participants. This trial has a need for 175 individuals across just one medical centre."
Share this study with friends
Copy Link
Messenger